Cellmat Therapeutics "Lost Lawsuit on Invalidity of eTrial New Share Issuance"
[Asia Economy Reporter Choi Dae-yeol] Cellmat Therapeutics confirmed on the 1st that although it acquired 2 million shares through Etrial's paid-in capital increase in June this year, the plaintiff won the lawsuit filed by the company's shareholder seeking invalidation of the new share issuance.
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Koo Yoon-chul: "$10.9 Billion Inflow After WGBI Inclusion... Accelerating Reforms in Forex and Capital Markets"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
